MoblO2 for Chronic Obstructive Pulmonary Disease

(SSeifert Trial)

This trial tests a new oxygen delivery device called MoblO2 for individuals with chronic lung diseases such as COPD or interstitial lung disease. The MoblO2 device automatically adjusts oxygen flow to maintain safe blood oxygen levels, potentially aiding in activity and improving quality of life. The trial examines whether this device facilitates physical activities and enhances patient satisfaction with oxygen therapy. Suitable participants include those with COPD or similar conditions who use oxygen during physical activity and have stable symptoms and oxygen needs. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could improve oxygen therapy for many.

Studies have shown that the MoblO2 device, designed for people with chronic lung diseases like COPD, is generally safe. Research indicates that the device adjusts oxygen flow based on individual needs, preventing both insufficient and excessive oxygen. This is crucial because too much oxygen can harm some patients with severe COPD.

The MoblO2 device uses a pulse oximeter, a small sensor, to monitor blood oxygen levels and adjusts the oxygen flow to maintain optimal levels. If the battery fails, the device continues to provide oxygen at the user's set level, reducing the risk of an unexpected oxygen shortage.

MoblO2 is unique because it focuses on controlling airflow in patients with Chronic Obstructive Pulmonary Disease (COPD) in a targeted way. Unlike standard treatments like bronchodilators and steroids that broadly open airways or reduce inflammation, MoblO2 aims to precisely regulate airflow, potentially offering a more tailored approach to managing symptoms. Researchers are excited about MoblO2 because it might provide quicker relief by directly managing the flow of air during specific periods, which could lead to better breathing efficiency and improved quality of life for COPD patients.

Research has shown that long-term oxygen therapy might not always improve outcomes for COPD patients, particularly those with mild oxygen level drops. In this trial, participants will experience two different approaches with the MoblO2 device. In one arm, MoblO2 controls the oxygen flow during the first week, while in the other arm, it controls the flow during the second week. The MoblO2 device aims to change the current understanding by automatically adjusting oxygen flow to stabilize blood oxygen levels, potentially reducing the burden on patients. Early results suggest that this technology can help maintain steady oxygen levels, which might improve physical activity and quality of life. This new approach could offer more convenience and less stress for patients who need oxygen therapy.³⁶⁷⁸⁹